SNS-101 is under clinical development by Sensei Biotherapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SNS-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SNS-101 overview

SNS-101 is under development for the treatment of solid tumors, non-small cell lung cancer, head and neck cancer, melanoma and colorectal cancer. It comprises of fully human monoclonal IgG1 antibody that has been designed to selectively binds active (low pH) VISTA. The drug candidate acts by targeting V-domain immunoglobulin (Ig)-containing suppressor of T-cell activation (VISTA). The drug candidate is developed based on TMAb (Tumor Microenvironment Activated biologics) platform. It is administered through intravenous route.

Sensei Biotherapeutics overview

Sensei Biotherapeutics (Sensei) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes innovative immuno-oncology medicines. The company offering products include SNS-101, SNS-102 and SNS-103. The company’s patented and proprietary technology platform SPIRIT, creates novel therapies that target neoantigens or altered self-antigens. Sensei is advancing a new class of immuno-oncology therapies to stimulate the immune system to recognize cancer-specific antigens and attack cancer cells. It develops and commercializes an integrated set of diagnostics and therapeutics for cancer. Sensei is headquartered in Rockville, Maryland, the US.

For a complete picture of SNS-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.